Biotech companies consider trade secrets as alternative to patents
Biotech IP practitioners at the BIO International Convention warned companies will increasingly look to trade secrets as a result of the courts’ and USPTO’s interpretation of Section 101, while David Kappos, Phil Johnson and Judge Paul Michel gave a gloomy outlook for patent holders
Speakers at the BIO International Convention in Philadelphia this month expressed concern about the effect of US court decisions related to Section 101 of the Patent Act. The Supreme Court has narrowed what is eligible under 101 in recent years...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.